| Literature DB >> 21696634 |
Juan Carlos Higareda-Almaraz1, María del Rocío Enríquez-Gasca, Magdalena Hernández-Ortiz, Osbaldo Resendis-Antonio, Sergio Encarnación-Guevara.
Abstract
BACKGROUND: Cervical cancer is a major mortality factor in the female population. This neoplastic is an excellent model for studying the mechanisms involved in cancer maintenance, because the Human Papilloma Virus (HPV) is the etiology factor in most cases. With the purpose of characterizing the effects of malignant transformation in cellular activity, proteomic studies constitute a reliable way to monitor the biological alterations induced by this disease. In this contextual scheme, a systemic description that enables the identification of the common events between cell lines of different origins, is required to distinguish the essence of carcinogenesis.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21696634 PMCID: PMC3152905 DOI: 10.1186/1752-0509-5-96
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Figure 1Pipeline. We compared the protein profiles of six cervical cancer cell lines by 2D SDS-PAGE, and established a set of proteins common to these cell lines, and which did not feature in our control. This set of proteins was termed "central core of cervical cancer", (a). From the central core, we reconstructed a PPI network (b), this network expanded and used to obtain the overrepresented GO's and pathways. Finally, we conducted an analysis of the transcription factors contained in the extended network using ChIP-Seq analysis of the ENCODE project (c).
Proteins identified as members of the "central core of cervical cancer".
| Accession number | Name | Score | Expect | Searched-Matched | Coverage |
|---|---|---|---|---|---|
| GRP78_HUMAN | 78 kDa glucose-regulated protein | 391 | 1.60E-035 | 91 - 46 | 58% |
| ENOA_HUMAN | Alpha-enolase | 327 | 4.00E-029 | 82 - 34 | 82% |
| GRP78_HUMAN | 79 kDa glucose-regulated protein | 302 | 1.30E-026 | 64 - 32 | 47% |
| HSP7C_HUMAN | Heat shock cognate 71 kDa protein | 294 | 8.10E-026 | 70 - 39 | 48% |
| VIME_HUMAN | Vimentin | 290 | 2.00E-025 | 64 - 33 | 63% |
| ENOA_HUMAN | Alpha-enolase | 286 | 5.10E-025 | 82 - 34 | 82% |
| PDIA1_HUMAN | Protein disulfide-isomerase | 252 | 1.30E-021 | 77 - 30 | 55% |
| ANXA2_HUMAN | Annexin A2 | 249 | 2.60E-021 | 65 - 31 | 72% |
| TBB5_HUMAN | Tubulin beta chain | 247 | 4.00E-021 | 73 - 32 | 62% |
| ANXA4_HUMAN | Annexin A4 | 233 | 1.00E-019 | 50 - 25 | 59% |
| EFTU_HUMAN | Elongation factor Tu, mitochondrial | 217 | 4.00E-018 | 44 - 22 | 52% |
| TPIS_HUMAN | Triosephosphate isomerase | 206 | 5.10E-017 | 42 - 17 | 69% |
| VIME_HUMAN | Vimentin | 206 | 5.10E-017 | 62 - 23 | 50% |
| PGAM1_HUMAN | Phosphoglycerate mutase 1 | 205 | 2.10E-016 | 41 - 18 | 58% |
| ATPB_HUMAN | ATP synthase subunit beta, mitochondrial | 193 | 1.00E-015 | 84 - 44 | 72% |
| ACTG_HUMAN | Actin, cytoplasmic 2 | 192 | 1.30E-014 | 50 - 20 | 48% |
| PUR9_HUMAN | Bifunctional purine biosynthesis protein PURH | 191 | 1.60E-015 | 49 - 22 | 45% |
| KCRB_HUMAN | Creatine kinase B-type | 178 | 3.20E-014 | 50 - 19 | 48% |
| EF2_HUMAN | Elongation factor 2 | 154 | 8.10E-012 | 67 - 26 | 33% |
| HYOU1_HUMAN | Hypoxia up-regulated protein 1 | 154 | 8.10E-012 | 38 - 19 | 22% |
| KCRB_HUMAN | Creatine kinase B-type | 154 | 8.10E-012 | 50 - 19 | 48% |
| PPIA_HUMAN | Peptidyl-prolyl cis-trans isomerase A | 150 | 2.00E-011 | 45 - 16 | 81% |
| GELS_HUMAN | Gelsolin | 147 | 4.00E-011 | 46 - 19 | 30% |
| VINC_HUMAN | Vinculin | 145 | 6.40E-011 | 36-19 | 20% |
| WDR1_HUMAN | WD repeat-containing protein 1 | 144 | 8.10E-011 | 46 - 16 | 31% |
| EZRI_HUMAN | Ezrin | 131 | 1.60E-009 | 60 - 26 | 34% |
| HSP71_HUMAN | Heat shock 70 kDa protein 1A/1B | 129 | 2.60E-009 | 42 - 21 | 33% |
| TBA1C_HUMAN | Tubulin alpha-1C chain | 127 | 4.00E-009 | 45 - 13 | 37% |
| PRDX1_HUMAN | Peroxiredoxin-1 | 126 | 5.10E-009 | 53 - 18 | 58% |
| PDIA3_HUMAN | Protein disulfide-isomerase A3 | 125 | 6.40E-009 | 47 - 15 | 28% |
| GRP75_HUMAN | Stress-70 protein, mitochondrial | 123 | 1.00E-008 | 81 - 34 | 43% |
| DHSA_HUMAN | Succinate dehydrogenase flavoprotein subunit | 122 | 3.30E-007 | 39 - 17 | 21% |
| RSSA_HUMAN | 40S ribosomal protein SA | 121 | 1.60E-008 | 37 - 11 | 34% |
| HS90B_HUMAN | Heat shock protein HSP 90-beta | 119 | 2.6e-08 | 44 - 19 | 27% |
| ESTD_HUMAN | S-formylglutathione hydrolase | 114 | 8.10E-008 | 25 - 11 | 41% |
| TKT_HUMAN | Transketolase | 114 | 8.10E-008 | 52 - 19 | 32% |
| LDHB_HUMAN | L-lactate dehydrogenase B chain | 112 | 1.30E-007 | 43 - 20 | 36% |
| AL1A1_HUMAN | Retinal dehydrogenase 1 | 110 | 2.00E-007 | 58 - 19 | 34% |
| IPYR_HUMAN | Inorganic pyrophosphatase | 110 | 2.00E-007 | 22 - 9 | 35% |
| DDX3X_HUMAN | ATP-dependent RNA helicase DDX3X | 108 | 3.20E-007 | 23 - 13 | 20% |
| DHE3_HUMAN | Glutamate dehydrogenase 1, mitochondrial | 107 | 4.00E-007 | 38 - 13 | 29% |
| G3P_HUMAN | Glyceraldehyde-3-phosphate dehydrogenase | 107 | 4.00E-007 | 55 - 13 | 42% |
| ACON_HUMAN | Aconitate hydratase, mitochondrial | 105 | 6.40E-007 | 54 - 23 | 30% |
| ML12A_HUMAN | Myosin regulatory light chain 12A | 105 | 6.40E-007 | 32 - 11 | 63% |
| RIR1_HUMAN | Ribonucleoside-diphosphate reductase large subunit | 101 | 1.60E-006 | 28 - 15 | 18% |
| EF2_HUMAN | Elongation factor 2 | 99 | 2.60E-006 | 60-20 | 29% |
| QCR1_HUMAN | Cytochrome b-c1 complex subunit 1, mitochondrial | 98 | 3.30E-006 | 45 - 15 | 29% |
| CNN2_HUMAN | Calponin-2 | 96 | 4.50E-006 | 51 - 13 | 48% |
| PCBP1_HUMAN | Poly(rC)-binding protein 1 | 94 | 8.30E-006 | 39 - 14 | 44% |
| IMMT_HUMAN | Mitochondrial inner membrane protein | 92 | 1.30E-005 | 34 - 13 | 20% |
| CAPG_HUMAN | Macrophage capping protein | 91 | 1.80E-005 | 41 - 11 | 30% |
| TCTP_HUMAN | Translationally-controlled tumor protein | 91 | 1.80E-005 | 19 - 8 | 40% |
| PSB4_HUMAN | Proteasome subunit beta type-4 | 89 | 1.70E-003 | 20 - 7 | 34% |
| TERA_HUMAN | Transitional endoplasmic reticulum ATPase | 88 | 3.10E-005 | 49 - 15 | 21% |
| K2C1_HUMAN | Keratin, type II cytoskeletal 1 | 87 | 3.70E-005 | 46 - 13 | 29% |
| LEG1_HUMAN | Galectin-1 | 84 | 7.70E-005 | 41 - 8 | 51% |
| 1433Z_HUMAN | 14-3-3 protein zeta/delta | 80 | 2.30E-004 | 43 - 14 | 54% |
| LMNA_HUMAN | Prelamin-A/C | 78 | 3.40E-004 | 37 - 11 | 22% |
| HNRPL_HUMAN | Heterogeneous nuclear ribonucleoprotein L | 77 | 4.10E-004 | 27 - 13 | 16% |
| TCPH_HUMAN | T-complex protein 1 subunit eta | 77 | 4.00E-004 | 36 - 15 | 30% |
| OSBL8_HUMAN | Oxysterol-binding protein-related protein 8 | 73 | 1.10E-003 | 56 - 13 | 21% |
| TCPE_HUMAN | T-complex protein 1 subunit epsilon | 71 | 1.70E-003 | 30 - 11 | 23% |
| HYOU1_HUMAN | Hypoxia up-regulated protein 1 | 70 | 2.20E-003 | 28 - 13 | 14% |
| PSA5_HUMAN | Proteasome subunit alpha type-5 | 69 | 2.70E-003 | 17 - 6 | 25% |
| FOXP3_HUMAN | Forkhead box protein P3 | 68 | 3.40E-003 | 41 - 12 | 34% |
The entry name corresponds to the UniProt database, the score and expect value were obtained from the search engine Mascot. The expect value is the number of matches with equal or better scores that are expected to occur by chance alone. Score as -10*LOG10(P), where P is the absolute probability. The lower the expectation value, the more significant the score.
Figure 2Network Reconstruction. Network of differentially expressed proteins in cervical cancer cell-lines compared to a non-cancerous control. The connections between proteins represent experimentally verified protein-protein interactions between 33 out of the 66 proteins identified in this study. The proteins not included in this network do not have experimentally proven interactions. The network was constructed using Cytoscape and the plugin Bisogenet.
Figure 3Overexpression of 14-3-3ζ. The expression levels of 14-3-3ζ in the six cervical cancer cell lines were assessed by western blot analysis. Whole brain extract was used a positive control, because 14-3-3ζ has a strong expression in this tissue. α-Tubulin was used as a loading control (Data not shown).
Figure 4Network Extension. Expanded network taking identified proteins as bait. Proteins belonging to our core of differentially expressed proteins were used as bait to fish protein-protein experimental interactions by adding neighbors of input nodes to a distance of up to one protein. This resulted in a network of 1,321 nodes and 9,666 edges. The network was expanded using Cytoscape and the plugin Bisogenet. Pink nodes represent the bait proteins, while the blue nodes correspond to the proteins that were included as a result of the network expansion.
Enriched gene ontology level 3 categories of biological processes.
| GO:0006986 | response to unfolded protein | 73 | 8 | 3.11E-009 | 7.03E-007 |
| GO:0070841 | inclusion body assembly | 13 | 4 | 4.26E-007 | 4.82E-005 |
| GO:0006091 | generation of precursor metabolites and energy | 363 | 11 | 2.02E-006 | 1.52E-004 |
| GO:0032507 | maintenance of protein location in cell | 80 | 6 | 3.14E-006 | 1.77E-004 |
| GO:0016052 | carbohydrate catabolic process | 132 | 7 | 4.67E-006 | 1.93E-004 |
| GO:0051651 | maintenance of location in cell | 87 | 6 | 5.13E-006 | 1.93E-004 |
| GO:0012501 | programmed cell death | 1338 | 20 | 7.18E-006 | 2.32E-004 |
| GO:0010941 | regulation of cell death | 1136 | 18 | 1.06E-005 | 2.99E-004 |
| GO:0046907 | intracellular transport | 855 | 15 | 2.08E-005 | 5.21E-004 |
| GO:0002349 | histamine production involved in inflammatory response | 2 | 2 | 2.56E-005 | 5.25E-004 |
| GO:0043455 | regulation of secondary metabolic process | 2 | 2 | 2.56E-005 | 5.25E-004 |
| GO:0002443 | leukocyte mediated immunity | 184 | 7 | 4.05E-005 | 7.64E-004 |
| GO:0044248 | cellular catabolic process | 1028 | 16 | 4.56E-005 | 7.92E-004 |
| GO:0050777 | negative regulation of immune response | 40 | 4 | 4.91E-005 | 7.93E-004 |
| GO:0070727 | cellular macromolecule localization | 610 | 12 | 5.29E-005 | 7.98E-004 |
| GO:0051235 | maintenance of location | 133 | 6 | 5.79E-005 | 8.18E-004 |
Set size refers to the number of entities that have a Uniprot ID as stated in the corresponding GO category at the ConsensusPathDB site. The number of candidates contained refers to amount of proteins identified in this study that appear as part of the GO category. P-values are calculated according to a hypergeometric test; q-values represent p-values corrected for multiple testing using the false discovery rate method.
Enriched KEGG pathway-based sets.
| Small cell lung cancer | 84 | 37 | 8.67E-009 | 1.43E-006 | KEGG |
| Protein processing in endoplasmic reticulur | 164 | 57 | 4.21E-008 | 3.47E-006 | KEGG |
| Pathways in cancer | 325 | 94 | 8.81E-008 | 4.05E-006 | KEGG |
| Apoptosis | 87 | 36 | 9.82E-008 | 4.05E-006 | KEGG |
| Neurotrophin signaling pathway | 125 | 46 | 1.24E-007 | 4.10E-006 | KEGG |
| T cell receptor signaling pathway | 108 | 41 | 2.25E-007 | 6.19E-006 | KEGG |
| Focal adhesion | 199 | 62 | 9.45E-007 | 2.23E-005 | KEGG |
| Prostate cancer | 89 | 33 | 6.11E-006 | 1.26E-004 | KEGG |
| Pathogenic Escherichia coli infection | 54 | 23 | 1.13E-005 | 2.07E-004 | KEGG |
| Endometrial cancer | 52 | 22 | 1.99E-005 | 3.28E-004 | KEGG |
| Shigellosis | 61 | 24 | 3.61E-005 | 5.42E-004 | KEGG |
| Non-small cell lung cancer | 54 | 22 | 4.03E-005 | 5.54E-004 | KEGG |
| Proteasome | 44 | 19 | 5.17E-005 | 6.56E-004 | KEGG |
| Bacterial invasion of epithelial cells | 70 | 26 | 5.59E-005 | 6.59E-004 | KEGG |
| B cell receptor signaling pathway | 75 | 27 | 7.62E-005 | 8.38E-004 | KEGG |
| Leukocyte transendothelial migration | 116 | 37 | 8.27E-005 | 8.53E-004 | KEGG |
Set size refers to the number of entities that have a Uniprot ID as stated in the corresponding KEGG pathway-based set at the ConsensusPathDB site. The number of candidates contained refers to amount of proteins which are part of the extended network and appear as part of the pathway. P-values are calculated according to a hypergeometric test; q-values represent p-values corrected for multiple testing using the false discovery rate method.
Significantly overrepresented transcription factors identified by ENCODE ChIP-Seq peaks based on the GENCODE Database
| E2F1 | HeLa-S3 | cervical | 187 | 1445 | 4.81E-013 |
| TCF4 | HCT-116 | colorectal | 244 | 2059 | 1.46E-012 |
| Pol2 | HeLa-S3 | cervical | 312 | 2878 | 3.93E-011 |
| c-Myc | HeLa-S3 | cervical | 123 | 880 | 5.52E-011 |
| Max | HeLa-S3 | cervical | 161 | 1266 | 9.77E-011 |
| E2F6 | k562 | Leukemia | 265 | 2379 | 1.17E-010 |
| NFKB | GM12878 | Lymphoblastoid | 111 | 794 | 5.02E-010 |
The peaks were mapped to regions corresponding to the promoter sequences as considered for this study (-700, 300 bp), based upon transcription start sites (TSS) annotated by GENCODE. Peaks near TSS of the genes of the extended network and all GENCODE genes refers to the amount of peaks found in the promoter region. P-values were calculated by a hypergeometric test. Sample size was considered as the amount of genes that corresponded to the proteins of the extended network. Population size was the number of annotated GENCODE entries that had a complete status and were separated by a distance of up to 500 base pairs.
Significantly overrepresented transcription factors identified by ENCODE ChIP-Seq peaks based on the TRED Database
| Pol2 | HeLa-S3 | cervical | 608 | 7766 | 2.15E-067 |
| TCF4 | HCT-116 | colorectal | 455 | 5543 | 1.93E-050 |
| E2F6 | k562 | Leukemia | 488 | 6343 | 1.12E-046 |
| Max | HeLa-S3 | cervical | 313 | 3375 | 2.90E-042 |
| c-Myc | HeLa-S3 | cervical | 250 | 2395 | 1.88E-041 |
| NFKB | GM12878 | Lymphoblastoid | 195 | 1802 | 6.78E-034 |
| E2F1-HA | HeLa-S3 | cervical | 315 | 4272 | 7.57E-024 |
ChIP-Seq peaks mapped to regions corresponding to the promoter sequences as considered for this study (-700, 300 bp), based upon transcription start sites (TSS) annotated by SwitchGear. Peaks near TSS of the genes of the extended network and reported on SwitchGear refers to the amount of peaks found in the corresponding promoter regions. P-values were calculated by a hypergeometric test. Sample size was considered as the amount of genes that corresponded to the proteins of the extended network. Population size was the number of reported TSS reported on SwitchGear with a score greater than 20.
Figure 5Model of Action of c-Myc, E2F1 and 14-3-3ζ. Model of the downstream events product of the overexpression and/or amplification of c-Myc, and its collaboration with the transcription factor E2F1. c-Myc promotes the expression of proteins that lead to survival and proliferation through processes such as metabolism, protein biosynthesis and transcription factors. Likewise, it enables the expression of proteins involved in epithelial mesenchymal transition. E2F1 and c-Myc work together to promote the expression of Cyclins and E2F factors that boost the transition between G1 and S phases of mitosis, as well as the expression of 14-3-3ζ and Bcl-2. Bcl-2 is an antiapoptotic protein that prevents the release of cytochrome c. The overexpression of 14-3-3ζ results in instability and degradation of p53, increased cell proliferation, and cytoplasmic sequestration of BAD with what brings drastic decrease of apoptosis.